In the longitudinal cohort (excluding participants with PDD at baseline), survival analyses showed a significantly shorter duration between PD symptom onset and diagnosis of PDD in GBA mutation carriers compared to non-mutation carriers (Fig. 3a). This evidence concerns the gene GBA1 and Parkinson disease.